COMMUNIQUÉS West-GlobeNewswire
-
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
17/05/2026 -
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
17/05/2026 -
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
17/05/2026 -
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
16/05/2026 -
Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients
16/05/2026 -
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
16/05/2026 -
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
16/05/2026 -
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
15/05/2026 -
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
15/05/2026 -
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
15/05/2026 -
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
15/05/2026 -
Trading in GN Store Nord shares by board members, executives and associated persons
15/05/2026 -
The Robotic Spine Institute of Las Vegas Announces Dr. Kornelis Poelstra’s Completion of 2,000 Robotic Spine Surgeries
15/05/2026 -
4DMT Announces New Employment Inducement Grants
15/05/2026 -
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
15/05/2026 -
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
15/05/2026 -
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
15/05/2026 -
Solana Company Reports First Quarter 2026 Financial Results
15/05/2026 -
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15/05/2026
Pages